Breaking News, Collaborations & Alliances

NanoBio, Merck Enter Adjuvant Technology Pact

Will use NanoStat platform for RSV and flu vaccine development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NanoBio Corp. has signed a licensing agreement with a subsidiary of Merck for the use of its nanoemulsion (NE) adjuvant technology for vaccine development.   Merck will have exclusive rights to NanoBio’s NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal flu and/or universal seasonal flu vaccine. NanoBio will receive an upfront payment and is eligible to receive development and regulatory milestones, as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters